| « Back |
 View printer-friendly version |
Vaccinex To Present at the 4th Annual Therapeutic Monoclonal Antibody Discovery Conference
ROCHESTER, NY – Vaccinex Inc., a biotechnology company focused on the development of novel immune-based therapeutics, announced today that Ernest Smith, Ph.D., Senior Vice President of Research and Chief Scientific Officer, will present details of the company’s propriety antibody selection technology during the 4th annual Therapeutic Monoclonal Antibody Discovery conference to be held in Boston, Massachusetts. The Company’s technology has been used to identify antibodies for clinical development for internal and external projects. Dr. Smith said, “I am very excited to be able to speak about our antibody selection technology, which has proven to be very effective at enabling the discovery of therapeutic quality human antibodies. In addition to this, for the first time, I will detail some of the new, path changing strategies that we are developing in the area of antibody discovery.” Slides from the presentation can be accessed at http://www.vaccinex.com/Collateral/Documents/English-US/1010.pdf.
About Vaccinex, Inc.
Vaccinex, Inc. is a biotechnology company engaged in the discovery and development of novel therapeutic antibodies. Utilizing its patented ActivMAb® antibody discovery technology, Vaccinex has developed the only library-based antibody discovery technology capable of directly expressing bivalent, fully human antibodies in mammalian cells. The company is building an impressive pipeline of therapeutic antibodies with the potential for effectively treating various autoimmune diseases and cancers. For additional information, please visit the company's website at www.vaccinex.com.
About Vaccinex, Inc.
Vaccinex, Inc. is a biotechnology company engaged in the discovery and development of novel therapeutic antibodies. Utilizing its patented ActivMAb® antibody discovery technology, Vaccinex has developed the only library-based antibody discovery technology capable of directly expressing bivalent, fully human antibodies in mammalian cells. The company is building an impressive pipeline of therapeutic antibodies with the potential for effectively treating various autoimmune diseases and cancers. For additional information, please visit the company's website at www.vaccinex.com.